Pneumococcal (PCV) Quarterly 90% 90% 90% 90% 90 3rd Dose Coverage (118 095 of (118 095 of (118 095 of (118 095 of (118 095 of 131 217) 131 217) 131 217) 131 217) 131 217) Rota Virus (RV) 2nd Quarterly 90% 90% 90% 90% 90 Dose Coverage (118 095 of (118 095 of (118 095 of (118 095 of (118 095 of 131 217) 131 217) 131 217) 131 217) 131 217) Diarrhoea incidence 180/1000 195/1000 population 190/1000 population 185/1000 population 180/1000 Quarterly under 5years population population Pneumonia incidence 60/1000 61.5/1000 population 61/1000 population 60.5/1000 population 60/1000 population Quarterly under 5 years population 55% 57% 59% 60% Cervical cancer 60% Quarterly screening coverage 565216 of 606322 of 616599 of 616599 of 1027665 1027665 1027665 1027665 585769 of 1027665 60% 60% 60% 60% 60% Ante natal visit before 20 Quarterly weeks rate <5 Baby tested PCR Positive Quarterly <5 <5 <5 <5 six weeks after birth as a proportion of babies tested at six weeks
Pneumococcal (PCV) 3rd Dose Coverage Quarterly 90 (118 095 of 131 217) 90% (118 095 of 131 217) 90% (118 095 of 131 217) 90% (118 095 of 131 217) 90% (118 095 of 131 217) Rota Virus (RV) 2nd Dose Coverage Quarterly 90 (118 095 of 131 217) 90% (118 095 of 131 217) 90% (118 095 of 131 217) 90% (118 095 of 131 217) 90% (118 095 of 131 217) Diarrhoea incidence under 5years Quarterly 180/1000 population 195/1000 population 190/1000 population 185/1000 population 180/1000 population Pneumonia incidence under 5 years Quarterly 60/1000 population 61.5/1000 population 61/1000 population 60.5/1000 population 60/1000 population Cervical cancer screening coverage Quarterly 60% 616599 of 1027665 55% 565216 of 1027665 57% 585769 of 1027665 59% 606322 of 1027665 60% 616599 of 1027665 Ante natal visit before 20 weeks rate Quarterly 60% 60% 60% 60% 60% Baby tested PCR Positive six weeks after birth as a proportion of babies tested at six weeks Quarterly <5 <5 <5 <5 <5